Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report issued to clients and investors on Wednesday. The firm set a “buy” rating on the stock.

Trinity Biotech Price Performance

TRIB stock opened at $1.85 on Wednesday. The stock has a market capitalization of $14.10 million, a PE ratio of -0.58 and a beta of 1.21. The company’s 50-day moving average is $2.06 and its 200-day moving average is $2.25. Trinity Biotech has a 1 year low of $1.79 and a 1 year high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings data on Wednesday, January 31st. The company reported ($0.90) earnings per share (EPS) for the quarter. The firm had revenue of $14.68 million for the quarter. On average, analysts anticipate that Trinity Biotech will post -1.5 earnings per share for the current fiscal year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.